Oct 20 (Reuters) – Novo Nordisk said on Tuesday its next-generation experimental drug, CagriSema, showed 25% weight loss on average in women with obesity or overweight, according to data analyzed
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Svea Herbst-Bayliss NEW YORK, Oct 20 (Reuters) - Activist investor Starboard Value on Tuesday…
By Paul Sandle LONDON, Oct 19 (Reuters) - Microsoft has pulled out of a deal…
Oct 20 (Reuters) - Deutsche Boerse AG: * DEUTSCHE BOERSE: RAISES ITS TOTAL NET REVENUE…
VIDEO SHOWS: BAYERN MUNICH ASSISTANT COACH AARON DANKS AND FORWARD SERGE GNABRY TALKING ABOUT ARSENAL…
WASHINGTON, Oct 20 - US President Donald Trump said on Tuesday that he will have…
FRANKFURT, Oct 20 (Reuters) - German sportswear maker Adidas on Tuesday raised its full-year profit…